Saturday 17 October 2026
Export SLS’s income statement to Excel — free account
SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million. In the quarter to June 2026, EPS grew 28.6% and free cash flow fell 3.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.98
1.36
−11.99%
Follow SLS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Piotroski F-Score |
— | — | — | — | — | — | 2 | — | — | — |
P/S ratio |
— | — | — | — | 6.12 | 7.24 | 4.71 | — | — | — |
Altman Z-Score |
— | — | — | — | (2.58) | (0.78) | (16.75) | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | (5.70) | (15.55) | (40.45) | — | — | — |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
P/Operating CF |
— | — | — | — | 13.54 | (17.20) | (9.60) | — | — | — |
P/B ratio |
— | — | — | — | 1.66 | 4.21 | 10.20 | — | — | — |
Price to Tangible BV |
— | — | — | — | 1.78 | 4.64 | 16.84 | — | — | — |
EV/Sales |
— | — | — | — | 1.56 | 5.48 | 3.11 | — | — | — |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
— | — | — | — | (1.14) | (2.49) | (1.37) | — | — | — |
EV/FCF |
— | — | — | — | (1.13) | (2.48) | (1.15) | — | — | — |
Quick Ratio |
1.05 | 0.52 | 0.91 | 1.45 | 2.87 | 4.31 | 1.11 | 0.19 | 1.47 | 10.25 |
Current Ratio |
1.11 | 0.53 | 0.98 | 1.56 | 2.99 | 4.63 | 1.14 | 0.23 | 1.72 | 10.72 |
Net Debt/EBITDA |
(0.08) | 0.08 | 0.25 | 0.37 | 2.12 | 0.85 | 0.41 | 0.07 | 0.44 | 2.54 |
Debt/Assets |
114.77% | 32.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.47) | 5.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.21 | 0.04 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.67 | 0.45 | 0.74 | 0.63 | 0.62 | 1.26 | 0.58 | 0.84 | 1.15 | 1.06 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Interest Coverage |
(13.71) | (49.87) | (116.88) | (169.84) | (653.15) | (4,215.67) | (132.33) | — | — | — |
| (415.24%) | 1,669.22% | (1,127.85%) | (493.05%) | (98.87%) | (85.70%) | (327.81%) | 2,389.76% | (4,147.88%) | (66.88%) | |
| (39.93%) | (122.31%) | (163.56%) | (166.75%) | (53.74%) | (57.24%) | (174.94%) | (274.94%) | (240.78%) | (54.95%) | |
ROIC |
0.00% | (4,675.12%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(2,847.18%) | 212.76% | 30,331.62% | (946.85%) | (68.47%) | (114.60%) | (1,842.97%) | 353.50% | (453.00%) | (39.39%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 488.53% | 281.24% | 3,026.80% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 505.26% | 148.95% | 1,258.20% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.06 | 0.11 | 0.12 | 0.04 | 0.07 | 0.09 | 0.31 | 0.10 | 0.02 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 30.42% | 88.30% | 172.60% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | 0.41 | 0.20 | 0.03 | — | — | — |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Earnings Yield |
— | — | — | — | (36.66%) | (24.05%) | (87.45%) | — | — | — |
Free Cash Flow Yield |
— | — | — | — | (22.64%) | (30.49%) | (57.25%) | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.49 | 0.05 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(626.98) | (234.81) | (116.11) | (6.89) | (1.31) | (1.68) | (1.23) | (1.13) | (0.58) | (0.26) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.46) | (0.20) | 0.00 | 0.00 |
Free Cash Flow per Share |
(626.98) | (234.81) | (116.11) | (6.89) | (1.31) | (1.68) | (1.69) | (1.33) | (0.58) | (0.26) |
Cash per Share |
319.95 | 272.44 | 20.81 | 2.88 | 4.44 | 1.39 | 0.89 | 0.09 | 0.23 | 0.66 |
Shareholders Equity per Share |
(264.39) | 44.23 | 20.02 | 2.38 | 3.51 | 1.31 | 0.25 | (0.29) | 0.15 | 0.65 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(264.39) | 44.23 | 20.02 | 2.38 | 3.51 | 1.31 | 0.25 | (0.29) | 0.15 | 0.65 |
Free Cash Flow |
(11.85) | (10.99) | (30.42) | (17.64) | (10.42) | (26.02) | (32.81) | (36.91) | (35.40) | (28.39) |
Working Capital |
0.62 | (11.48) | (0.14) | 2.95 | 24.59 | 18.06 | 2.24 | (10.56) | 6.82 | 68.19 |
Capital Expenditures |
— | — | — | — | — | — | (9.00) | (5.50) | 0.00 | — |
Net Current Asset Value |
(5.04) | (18.37) | (5.83) | (2.27) | 18.84 | 17.12 | 1.66 | (11.02) | 6.36 | 67.74 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
— | — | — | — | 0.00 | 0.00 | 9.00 | 0.00 | 0.00 | — |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 11.44 | — | — | — |
Cash ROIC |
(140.77%) | (42.58%) | (284.42%) | (130.98%) | (16.44%) | (62.25%) | (148.62%) | 690.42% | (150.96%) | (19.89%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.04 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,912.80 | 12,253.05 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | 2.00 | — | — | — | — | — | — |
Average Payables |
— | 6.64 | 7.72 | 3.83 | 4.28 | 3.40 | 2.75 | 4.50 | 4.57 | 3.22 |
Average Assets |
44.28 | 19.97 | 25.22 | 16.76 | 31.33 | 36.16 | 23.61 | 13.58 | 12.83 | 48.89 |
Average Common Equity |
4.26 | (1.46) | 3.66 | 5.67 | 17.03 | 24.15 | 12.60 | (1.56) | 0.74 | 40.17 |
Columns are period end dates